REGENERON PHARMACEUTICALS, INC. - FORM 10-K - EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - February 12, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - REGENERON PHARMACEUTICALS, INC.Financial_Report.xls
EX-10.25.3 - 3RD AMENDMENT BETWEEN CREDIT SUISSE AND THE REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10253x12312014x10k.htm
EX-21.1 - SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. - REGENERON PHARMACEUTICALS, INC.regn-ex_211x12312014x10k.htm
EX-10.25.2 - 2ND AMENDMENT BETWEEN CREDIT SUISSE AND THE REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10252x12312014x10k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_311x12312014x10k.htm
EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - REGENERON PHARMACEUTICALS, INC.regn-ex_231x12312014x10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_312x12312014x10k.htm
EX-10.21.2 - 2ND AMENDMENT BETWEEN GOLDMAN SACHS AND THE REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10212x12312014x10k.htm
10-K - 10-K - REGENERON PHARMACEUTICALS, INC.regn-123114x10k.htm
EX-10.10.1 - RESTATED AMENDMENT AGREEMENT BY AND BETWEEN BAYER HEALTHCARE AND THE REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10101x12312014x10k.htm
Exhibit 32
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Regeneron Pharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Leonard S. Schleifer
Leonard S. Schleifer, M.D., Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
February 12, 2015
 
/s/ Robert E. Landry
Robert E. Landry
Senior Vice President, Finance and Chief Financial Officer
(Principal Financial Officer)
February 12, 2015



REGENERON PHARMACEUTICALS, INC. Reports